Olanzapin viste sig statistisk signifikant overlegen overfor placebo på det primære slutpunkt for bipolære tilbagefald.
In a 12-month recurrence prevention study in manic episode patients who achieved remission on olanzapine and were then randomised to olanzapine or placebo, olanzapine demonstrated statistically significant superiority over placebo on the primary endpoint of bipolar recurrence.